Inducing tumor suppression and lymphocytotoxicityDecreasing Tregs and increasing the infiltration of CD45+ immune cells and CD4+ or CD8+ T cellsInducing the release of IFN-γ, perforin, and granzymeExtending the OS rate compared with monotherapy with M1. Here, PTPRC is linked to neoplasm.